CALGB 9741 — Dose-Dense Versus Conventionally Scheduled Adjuvant Chemotherapy for Node-Positive Breast Cancer

Phase 3 · 2003 · Breast Cancer

Design

2x2 design comparing every-2-week (dose-dense, with filgrastim support) vs every-3-week schedules of doxorubicin, cyclophosphamide, and paclitaxel.

Population

Resected node-positive breast cancer.

Primary Endpoint

disease-free survival (DFS)

Key Result

Dose-dense scheduling improved DFS (HR 0.74) and OS (HR 0.69) with manageable toxicity.

Guideline Impact

Dose-dense AC-T adopted as a preferred adjuvant regimen in NCCN guidelines